Innovation Pharmaceuticals Inc.
IPIXDrugs in Pipeline
32
Phase 3 Programs
7
Upcoming Catalysts
9
Next Catalyst
Oct 2026
Market Overview
Stock performance and key metrics
9 upcoming, 1 past
SMZ1
Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
0.05% atropine eye drops
Myopia
Gemcitabine hydrochloride and albumin binding paclitaxel
Locally Advanced Pancreatic Cancer
Cenerimod
Lupus Erythematosus, Systemic
Ivosidenib 500mg
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
F14
Post Operative Pain
Reference Drug
Retinal Vein Occlusion With Macular Edema
S095018
Non-small Cell Lung Cancer (NSCLC)
NTI164
PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
GI-108
Advanced Solid Tumor
THR-184
Acute Kidney Injury
Selatogrel 8 mg
Acute Myocardial Infarction
temelimab 18 mg/kg
Multiple Sclerosis
Standard of Care (SoC)
COVID-19
GNbAC1
Multiple Sclerosis
PRS-344/S095012
Solid Tumor
GI-102 subcutaneous (SC)
Advanced Solid Tumor
Selatogrel
Stable Coronary Artery Disease
SOM0226
Familial Amyloid Polyneuropathy (FAP)
S095035
MTAP-deleted Solid Tumors
SOM3355 200 mg capsules
Huntington Chorea
Ivosidenib
IDH1-mutant Cholangiocarcinoma
S095029
MSI-H/dMMR Gastroesophageal-junction Cancer
Cenerimod 0.5 mg
Systemic Lupus Erythematosus
GI-101
Advanced Solid Tumor
Bupivacaine HCl
Total Knee Replacement
Kevetrin
Ovarian Cancer
Brilacidin
Head and Neck Neoplasms
400 mg (200 mg BID)
Chronic Stable Plaque Psoriasis
JI-101
Advanced Solid Tumors
SOM3355 100mg BID
Huntington's Chorea
ANO31905
Pancreatic Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SMZ1 | Phase 3 | Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy | - | - |
0.05% atropine eye drops | Phase 3 | Myopia | - | - |
Gemcitabine hydrochloride and albumin binding paclitaxel | Phase 3 | Locally Advanced Pancreatic Cancer | - | - |
Cenerimod | Phase 3 | Lupus Erythematosus, Systemic | - | - |
Ivosidenib 500mg | Phase 3 | Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen | - | - |
F14 | Phase 3 | Post Operative Pain | - | - |
Reference Drug | Phase 3 | Retinal Vein Occlusion With Macular Edema | - | - |
S095018 | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | - | - |
NTI164 | Phase 2 | PANS Pediatric Acute-Onset Neuropsychiatric Syndrome | - | - |
GI-108 | Phase 2 | Advanced Solid Tumor | - | - |
THR-184 | Phase 2 | Acute Kidney Injury | - | - |
Selatogrel 8 mg | Phase 2 | Acute Myocardial Infarction | - | - |
temelimab 18 mg/kg | Phase 2 | Multiple Sclerosis | - | - |
Standard of Care (SoC) | Phase 2 | COVID-19 | - | - |
GNbAC1 | Phase 2 | Multiple Sclerosis | - | - |
PRS-344/S095012 | Phase 2 | Solid Tumor | - | - |
GI-102 subcutaneous (SC) | Phase 2 | Advanced Solid Tumor | - | - |
Selatogrel | Phase 2 | Stable Coronary Artery Disease | - | - |
SOM0226 | Phase 2 | Familial Amyloid Polyneuropathy (FAP) | - | - |
S095035 | Phase 2 | MTAP-deleted Solid Tumors | - | - |
SOM3355 200 mg capsules | Phase 2 | Huntington Chorea | - | - |
Ivosidenib | Phase 2 | IDH1-mutant Cholangiocarcinoma | - | - |
S095029 | Phase 2 | MSI-H/dMMR Gastroesophageal-junction Cancer | - | - |
Cenerimod 0.5 mg | Phase 2 | Systemic Lupus Erythematosus | - | - |
GI-101 | Phase 2 | Advanced Solid Tumor | - | - |
Bupivacaine HCl | Phase 2 | Total Knee Replacement | - | - |
Kevetrin | Phase 2 | Ovarian Cancer | - | - |
Brilacidin | Phase 2 | Head and Neck Neoplasms | - | - |
400 mg (200 mg BID) | Phase 2 | Chronic Stable Plaque Psoriasis | - | - |
JI-101 | Phase 2 | Advanced Solid Tumors | - | - |
SOM3355 100mg BID | Phase 2 | Huntington's Chorea | - | - |
ANO31905 | Phase 2 | Pancreatic Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Innovation Pharmaceuticals Inc.'s drug pipeline?→
CatalystAlert tracks 32 drug candidates in Innovation Pharmaceuticals Inc.'s (IPIX) pipeline across Phase 3, Phase 2. Its lead program is SMZ1 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Innovation Pharmaceuticals Inc.'s next FDA catalyst?→
Innovation Pharmaceuticals Inc.'s (IPIX) next tracked catalyst is a Phase 2 expected August 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IPIX biotech catalysts?→
Add IPIX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Innovation Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.